An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker protein

Martin F. Orth, Alex Cazes, Elke Butt and Thomas G. P. Grunewald _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:26-42. https://doi.org/10.18632/oncotarget.3083

Metrics: PDF 3285 views  |   HTML 5049 views  |   ?  


Martin F. Orth1, Alex Cazes1, Elke Butt1 and Thomas G. P. Grunewald2

1 Institute for Clinical Biochemistry and Pathobiochemistry, University Clinic of Würzburg, Grombühlstrasse, Würzburg, Germany

2 Laboratory for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Thalkirchner Strasse, Munich, Germany


Thomas Grunewald, email:

Keywords: LASP1, cancer, biomarker, microRNA, nucleo-cytoplasmic

Received: December 16, 2014 Accepted: December 28, 2014 Published: December 31, 2014


The gene encoding the LIM and SH3 domain protein (LASP1) was cloned two decades ago from a cDNA library of breast cancer metastases. As the first protein of a class comprising one N-terminal LIM and one C-terminal SH3 domain, LASP1 founded a new LIM-protein subfamily of the nebulin group. Since its discovery LASP1 proved to be an extremely versatile protein because of its exceptional structure allowing interaction with various binding partners, its ubiquitous expression in normal tissues, albeit with distinct expression patterns, and its ability to transmit signals from the cytoplasm into the nucleus. As a result, LASP1 plays key roles in cell structure, physiological processes, and cell signaling. Furthermore, LASP1 overexpression contributes to cancer aggressiveness hinting to a potential value of LASP1 as a cancer biomarker.

In this review we summarize published data on structure, regulation, function, and expression pattern of LASP1, with a focus on its role in human cancer and as a biomarker protein. In addition, we provide a comprehensive transcriptome analysis of published microarrays (n=2,780) that illustrates the expression profile of LASP1 in normal tissues and its overexpression in a broad range of human cancer entities.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3083